221 related articles for article (PubMed ID: 10826316)
1. Management of patients with cancer of unknown primary site.
Hainsworth JD; Greco FA
Oncology (Williston Park); 2000 Apr; 14(4):563-74; discussion 574-6, 578-9. PubMed ID: 10826316
[TBL] [Abstract][Full Text] [Related]
2. Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD
Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028
[TBL] [Abstract][Full Text] [Related]
3. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
[TBL] [Abstract][Full Text] [Related]
4. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
Hainsworth JD; Johnson DH; Greco FA
J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
[TBL] [Abstract][Full Text] [Related]
6. The evolving role of paclitaxel for patients with carcinoma of unknown primary site.
Greco FA; Hainsworth JD
Semin Oncol; 1999 Feb; 26(1 Suppl 2):129-33. PubMed ID: 10190795
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
Pentheroudakis G; Briasoulis E; Kalofonos HP; Fountzilas G; Economopoulos T; Samelis G; Koutras A; Karina M; Xiros N; Samantas E; Bamias A; Pavlidis N;
Acta Oncol; 2008; 47(6):1148-55. PubMed ID: 18607872
[TBL] [Abstract][Full Text] [Related]
8. Carcinoma of unknown primary site.
Greco FA; Burris HA; Erland JB; Gray JR; Kalman LA; Schreeder MT; Hainsworth JD
Cancer; 2000 Dec; 89(12):2655-60. PubMed ID: 11135228
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
Hainsworth JD; Spigel DR; Thompson DS; Murphy PB; Lane CM; Waterhouse DM; Naot Y; Greco FA
Oncologist; 2009 Dec; 14(12):1189-97. PubMed ID: 19965914
[TBL] [Abstract][Full Text] [Related]
10. [Metastatic carcinoma of unknown origin].
Fizazi K; Culine S
Bull Cancer; 1998 Jul; 85(7):609-17. PubMed ID: 9752267
[TBL] [Abstract][Full Text] [Related]
11. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site.
Greco FA; Hainsworth JD
Semin Oncol; 1989 Aug; 16(4 Suppl 6):116-22. PubMed ID: 2669133
[TBL] [Abstract][Full Text] [Related]
12. Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature.
Amela EY; Lauridant-Philippin G; Cousin S; Ryckewaert T; Adenis A; Penel N
Crit Rev Oncol Hematol; 2012 Nov; 84(2):213-23. PubMed ID: 22503530
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
Hainsworth JD; Daugaard G; Lesimple T; Hübner G; Greco FA; Stahl MJ; Büschenfelde CM; Allouache D; Penel N; Knoblauch P; Fizazi KS
Cancer; 2015 May; 121(10):1654-61. PubMed ID: 25611313
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
Hainsworth JD; Spigel DR; Litchy S; Greco FA
J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
[TBL] [Abstract][Full Text] [Related]
15. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
Greco FA; Johnson DH; Hainsworth JD
Semin Oncol; 1992 Dec; 19(6 Suppl 13):14-8. PubMed ID: 1492223
[TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
Kato S; Yasuda K; Nishino Y; Ohori H; Takahashi M; Takahashi S; Yamaura G; Ohtsuka K; Kakudo Y; Chiba N; Shimodaira H; Sakayori M; Kato S; Suzuki T; Murakawa Y; Gamoh M; Shibata H; Yoshioka T; Ishioka C
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1227-31. PubMed ID: 17687203
[TBL] [Abstract][Full Text] [Related]
17. Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site.
Hainsworth JD; Dial TW; Greco FA
Am J Clin Oncol; 1988 Apr; 11(2):138-45. PubMed ID: 2451881
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?
Pentheroudakis G; Briasoulis E; Karavassilis V; Fountzilas G; Xeros N; Samelis G; Samantas E; Pavlidis N
Acta Oncol; 2005; 44(2):155-60. PubMed ID: 15788295
[TBL] [Abstract][Full Text] [Related]
19. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
[TBL] [Abstract][Full Text] [Related]
20. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site.
Hainsworth JD; Greco FA
Semin Oncol; 1993 Jun; 20(3):279-86. PubMed ID: 8503024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
